jump to content jump to footer

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Research with mint mintLesion Clinical Research Standardized Reading Procedures iRECIST RECIST

Related Resources

Research poster presentation on standardized tumor response assessments using mint Lesion at the NCCN Annual Conference 2026
Presentation of a research poster by Memorial Sloan Kettering Cancer Center on the use of mint Lesion for structured tumor response assessments and clinical research workflows.
NCCN 2026: Memorial Sloan Kettering Cancer Center Presents Research on Structured Tumor Response Assessments with mint Lesion
Big congratulations to Steven Philemond and Alison Chiaramonte of Memorial Sloan Kettering Cancer Center for presenting their research poster “Use of…
Radiologist using mint Lesion for structured reporting and AI-supported workflows in lung cancer screening
How radiology practices can participate in lung cancer screening in Germany with mint Lesion through structured reporting, AI-supported workflows, and integrated collaboration with second-reading centers.
How Radiology Practices Can Participate in Germany’s Lung Cancer Screening Program with mint Lesion
New opportunities - but also economic uncertainty With the launch of lung cancer screening (LCS) in Germany, radiology practices are facing a new…
Hospital staff using mint Lesion for interoperable workflows and data management in lung cancer screening
How mint Lesion supports hospitals and screening centers with interoperable infrastructure, AI integration, data management, and scalable workflows for lung cancer screening.
Lung Cancer Screening in Germany: How mint Lesion Supports Hospitals with Infrastructure, Integration, and Scalability
Screening as a Strategic Challenge With the launch of the national lung cancer screening program in 2026, hospitals and screening centers across…